

Journal of Visualized Experiments

Isolation of Endothelial Cells from the Lumen of Mouse Carotid Arteries for Single-cell Multi-omics Experiments --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE63128R2
Full Title:	Isolation of Endothelial Cells from the Lumen of Mouse Carotid Arteries for Single-cell Multi-omics Experiments
Corresponding Author:	Hanjoong Jo Emory University and Georgia Institute of Technology Atlanta, GA UNITED STATES
Corresponding Author's Institution:	Emory University and Georgia Institute of Technology
Corresponding Author E-Mail:	hjo@emory.edu
Order of Authors:	Sandeep Kumar Aitor Andueza Juyoung Kim Dong Kang Hanjoong Jo
Additional Information:	
Question	Response
Please specify the section of the submitted manuscript.	Biology
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (\$1400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Atlanta, GA, USA
Please confirm that you have read and agree to the terms and conditions of the author license agreement that applies below:	I agree to the Author License Agreement
Please confirm that you have read and agree to the terms and conditions of the video release that applies below:	I agree to the Video Release
Please provide any comments to the journal here.	

TITLE:

Isolation of Endothelial Cells from the Lumen of Mouse Carotid Arteries for Single-cell Multi-omics Experiments

AUTHORS AND AFFILIATIONS:

Sandeep Kumar^{1§}, Aitor Andueza^{1§}, Juyoung Kim¹, Dong-Won Kang¹, Hanjoong Jo^{1,2}

¹Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA

²Division of Cardiology, Georgia Institute of Technology and Emory University, Atlanta, GA, USA

[§] Equal contribution

Email addresses of co-authors:

Sandeep Kumar	(sandeepkumar@emory.edu)
Aitor Andueza	(aanduez@emory.edu)
Juyoung Kim	(juyoungkim@gmail.com)
Dong-Won Kang	(dkang9@emory.edu)

Corresponding author:

Hanjoong Jo (hanjoong.jo@bme.gatech.edu)

KEYWORDS:

Artery cells, Endothelial cells, single-cell RNAseq, single-cell ATACseq, Atherosclerosis

SUMMARY:

We present a method for isolating endothelial cells and nuclei from the lumen of mouse carotid arteries exposed to stable or disturbed flow conditions to perform single-cell omics experiments.

ABSTRACT:

Atherosclerosis is an inflammatory disease of the arterial regions exposed to disturbed blood flow (*d-flow*). *D-flow* regulates the expression of genes in the endothelium at the transcriptomic and epigenomic levels, resulting in proatherogenic responses. Recently, single-cell RNA sequencing (scRNAseq) and single-cell Assay for Transposase Accessible Chromatin sequencing (scATACseq) studies were performed to determine the transcriptomic and chromatin accessibility changes at a single-cell resolution using the mouse partial carotid ligation (PCL) model. As endothelial cells (ECs) represent a minor fraction of the total cell populations in the artery wall, a luminal digestion method was used to obtain EC-enriched single-cell preparations. For this study, mice were subjected to PCL surgery to induce *d-flow* in the left carotid artery (LCA) while using the right carotid artery (RCA) as a control. The carotid arteries were dissected out two days or two weeks post PCL surgery. The lumen of each carotid was subjected to collagenase digestion, and endothelial-enriched single cells or single nuclei were obtained. These single-cell and single-nuclei preparations were subsequently barcoded using a 10x Genomics microfluidic setup. The barcoded single-cells and single-nuclei were then utilized for RNA preparation, library generation,

and sequencing on a high-throughput DNA sequencer. Post bioinformatics processing, the scRNAseq and scATACseq datasets identified various cell types from the luminal digestion, primarily consisting of ECs. Smooth muscle cells, fibroblasts, and immune cells were also present. This EC-enrichment method aided in understanding the effect of blood flow on the endothelium, which could have been difficult with the total artery digestion method. The EC-enriched single-cell preparation method can be used to perform single-cell omics studies in EC-knockouts and transgenic mice where the effect of blood flow on these genes has not been studied. Importantly, this technique can be adapted to isolate EC-enriched single cells from human artery explants to perform similar mechanistic studies.

INTRODUCTION:

This laboratory previously demonstrated that induction of *d-flow* leads to quick and rugged atherosclerosis development in hyperlipidemic mice^{1,2}. The novel mouse model of *d-flow*-induced atherosclerosis was possible using partial carotid ligation (PCL) surgery³. PCL surgery induces low and oscillatory blood flow condition or *d-flow* in the ligated left carotid artery (LCA). In contrast, the contralateral right carotid artery (RCA) continues to face stable laminar flow (*s-flow*). Previously, to understand the effect of *d-flow* on endothelial cells, the carotid arteries were dissected out after partial ligation surgery and flushed with a phenol and guanidine isothiocyanate-based lysing agent (luminal RNA/DNA flushing method)^{2,4}, which provided endothelial-enriched "pooled bulk" RNAs or DNAs. These pooled bulk RNAs or DNAs were then processed for transcriptomic studies or epigenomic DNA methylome studies, respectively⁴⁻⁶. These studies helped discover multiple flow-sensitive genes and microRNAs whose roles in endothelial biology and atherosclerosis were extensively investigated^{4,6,7}.

However, despite endothelial enrichment, these bulk RNA/DNA studies could not distinguish the specific role of each cell type in the artery wall in *d-flow*-induced atherosclerosis. Endothelial-enriched single-cell isolation and single-cell (sc)RNA and scATAC sequencing studies were performed to overcome this limitation⁸. For this, C57Bl6 mice were subjected to the PCL surgery to induce *d-flow* in the LCA while using the *s-flow*-exposed RCA as control. Two days or two weeks after the PCL surgery, the mice were sacrificed, and the carotids were dissected and cleaned up. The lumen of both LCAs and RCAs were infused with collagenase, and the luminal collagenase digests containing ECs as a significant fraction and other arterial cells were collected. The single-cell suspension (scRNAseq) or single-nuclei suspension (scATACseq) were prepared and barcoded with unique identifiers for each cell or nucleus using a 10x Genomics setup. The RNAs were subjected to cDNA library preparation and sequenced.

The scRNAseq and scATACseq datasets were processed using the Cell Ranger Single-Cell Software and further analyzed by Seurat and Signac R packages^{9,10}. Each cell and nucleus was assigned a cell type from these analyses and clustered into the cell type based on the marker genes and unique gene expression patterns. The results of the scRNAseq and scATACseq demonstrated that these single-cell preparations are enriched with ECs and also contain smooth muscle cells (SMCs), fibroblasts, and immune cells.

Further analysis revealed that the EC population in the luminal digestion is highly divergent and

plastic (8 different EC clusters) and responsive to blood flow. Most importantly, these results demonstrated that *d-flow* reprograms ECs from an athero-protected anti-inflammatory phenotype to pro-atherogenic phenotypes, including pro-inflammatory, endothelial-to-mesenchymal transition, endothelial stem/progenitor cell transition, and most surprisingly, endothelial-to-immune cell-like transition. In addition, scATACseq data reveal novel flow-dependent chromatin accessibility changes and transcription factor binding sites in a genome-wide manner, which form the basis of several new hypotheses. The methodology and protocol for preparing single endothelial cells for single-cell multi-omics studies from the mouse carotid arteries are detailed below.

PROTOCOL:

All animal procedures described below were approved by the Institutional Animal Care and Use Committee at Emory University. Non-hypercholesterolemic, age- and sex-matched C57BL/6 mice were used to mitigate sex-dependent variation and offset any complication of hypercholesterolemic conditions.

1. Partial carotid ligation (PCL) surgery

NOTE: Partial carotid artery ligation of LCA was carried out as previously described and demonstrated³.

1.1. Anesthetize the mouse by isoflurane inhalation (5% isoflurane in oxygen for induction and 1.5% after that for maintenance) throughout the procedure using an anesthetic vaporizer.

1.2. Apply an ocular ointment to prevent exposure keratitis, and confirm the depth of anesthesia by the absence of toe pinch response.

1.3. Inject buprenorphine 0.05 mg/kg subcutaneously to manage pain preemptively. Disinfect the epilated area by applying and cleaning with betadine and isopropanol solution three times. Ensure that betadine is the last step to sterilize the surgery area, starting from the center and finishing at the sides.

1.4. Using aseptic techniques, make a ventral midline incision (~1 cm) in the neck region, and expose the LCA branch point by blunt dissection.

1.5. Ligate the left internal carotid, external carotid, and occipital arteries with 6-0 silk suture; leave the superior thyroid artery untouched.

1.6. Approximate the skin and close the incision with tissue glue and/or sutures.

1.7. Transfer the mouse to a pre-warmed recovery cage (maintained at 37 °C) and place it on a clean towel for up to 1 h to avoid post-surgery hypothermia.

NOTE: If performed correctly, there is no mortality associated with this procedure, and postoperative stress to the mouse is minimal.

1.8. Prepare the perfusion setup.

1.8.1. Use 0.9% NaCl (normal saline) containing 10 U/mL heparin in an IV bag. Hook the IV bag 244–274 cm (8–9 feet) from the ground or approximately 122–152 cm (4–5 feet) higher than the dissection board. Attach the butterfly needle to the end of the saline line and flush any air bubbles out of the IV line.

2. Isolation of carotid arteries post sacrifice

2.1. Sacrifice the mice by CO₂ inhalation following the institutional IACUC protocol.

2.2. Spray 70% ethanol on the mouse skin and place it in the supine position on the dissection board containing adsorbent paper towels. Secure the paws of the mouse to the adsorbent towels on the dissection board using adhesive tape or a 21 G needle.

2.3. Using a pair of sterile scissors, remove the skin of the mouse starting from the abdomen and all the way to the top of the thorax.

2.4. Use a pair of scissors to open the abdominal wall below the ribcage by blunt dissection.

2.5. Using the scissors, carefully make an incision along the length of the diaphragm, and continue through the ribs on both sides of the thorax until the sternum can be lifted away. Gently lift away the sternum with a pair of forceps; after that, remove the ribcage to expose the heart.

2.6. Carefully remove the thymus and any connective tissue over the heart to visualize the major vessels.

2.7. Sever the vena cava with scissors to allow blood to exit from closed circulation.

2.8. Insert a 21 G butterfly needle connected to the IV line through the apex of the heart into the left ventricle and allow retrograde perfusion for 2–3 min with normal saline at room temperature. Ensure that a constant flow rate of normal saline is maintained by keeping the saline bag at the height of 8–9 feet from the ground.

NOTE: The lungs and liver become pale, indicating optimal perfusion. Approximately 20 mL of perfusion buffer is used for each mouse.

2.9. Remove the skin from the neck region and remove all the fat, muscles, and connective tissues to expose the carotid arteries (**Figure 1A**).

NOTE: The rest of the procedure is carried out under the dissecting microscope.

2.10. Adjust the field of view to locate the ligation sites. Using the 10 mm micro-dissection scissors, make a small incision below the ligation site in the LCA to allow perfusion.

2.11. Perfuse again for an additional 1 min via the left ventricle and ensure that the LCA is well perfused and free from any visible traces of blood.

2.12. Use fine-tip forceps and small spring scissors to carefully remove the peri-adventitial tissues surrounding the carotids while the carotid is attached to the body.

NOTE: Be extremely careful not to squeeze or stretch the carotid arteries during this cleaning step, as this can increase the number of non-viable cells. If performed correctly, the cell viability in the final cell suspension is usually >93%.

3. Endothelial-cell-enriched single-cell isolation from mice carotids

NOTE: The reagents described below can be prepared in advance and stored at 4 °C until use: 1x and 0.1x single-nuclei lysis buffers with the reagents listed in **Table 1**; single-nuclei wash buffer with the reagents listed in **Table 1**; single-nuclei Nuclei Buffer recipe with the reagents listed in **Table 1**. The working stocks of these buffers are to be prepared following the manufacturer's protocol. **Digestion buffer composition:** Collagenase Type II 600 U/mL and DNase I 60 U/mL in 0.5% fetal bovine serum (FBS)-containing phosphate-buffered saline (PBS).

3.1. While the carotids are still attached, wash the exterior of the carotid arteries with normal saline solution to flush away any traces of blood.

3.2. Using an insulin syringe fitted with a 29 G needle, inject ~ 50 µL of the digestion buffer into the lumen of the distal end of the left carotid artery. As the digestion buffer starts to fill the carotid artery, clamp the proximal end of the carotid with a micro-clip (**Figure 1B**). Introduce an additional 15–20 µL of digestion buffer into the lumen and clip the distal end to avoid the release of the digestion buffer.

3.3. Carefully explant the carotid arteries from the mouse (**Figure 1B,C**) and place them in 35 mm dishes containing warm (at 37 °C) HEPES-buffered saline solution.

NOTE: Make sure that both the clamps are securely placed. If the clamp becomes loose, the digestion solution can leak out of the lumen and affect the obtained cell count. If this happens, add additional enzymatic solution using an insulin syringe fitted with a 29 G needle from the open end of the carotid and secure the clamp again (**Figure 1D**). If the enzyme buffer solution leaks again, it is likely that the carotid is severed during the explantation process. In this case, discard the carotid and exclude the sample from the study. Repeated rough handling of the carotid will decrease the cell viability and the quality of single-cell preparation. **Take care to identify and correctly label the left and right carotid arteries.**

3.4. Incubate the explanted carotids for 45 min at 37 °C with intermittent rocking.

4. Flushing the carotid arteries

4.1. After completing the luminal enzymatic digestion, remove the carotid artery together with the clamps from the 35 mm dish. Carefully remove each clamp, taking care that the digestion buffer should not leak.

4.2. Gently hold one end of the carotid artery with fine forceps on top of a 1.5 mL microcentrifuge tube. Insert a 29 G needle fitted with an insulin syringe containing 100 µL of warm digestion buffer (37 °C) into the lumen with the other hand (**Figure 1D**).

4.3. Quickly flush the lumen of the carotid into the microcentrifuge tube. Block the enzymatic reaction by adding 0.3 mL of FBS into the 1.5 mL tube. Place the tube on ice.

NOTE: The flushing contains the cells from the luminal enzymatic digestion. Adding FBS and reducing the temperature stops the enzymatic digestion process. If the number of cells in the preparation is high and contains debris or fat tissue, the use of a 50 or 70 µm cell strainer is highly recommended to filter out unwanted tissues debris. To increase the single-cell count, flushing multiple carotids is recommended. Here, to obtain at least 5,000 cells, 10–12 carotids were flushed and pooled as one sample.

4.4. Centrifuge the cells at $500 \times g$ for 5 min at 4 °C using a centrifuge equipped with a fixed-angle rotor (see the **Table of Materials**).

4.5. Discard the supernatant and resuspend the cell pellet in digestion buffer containing cell dissociation reagent (see the **Table of Materials**) for 5 min at 37 °C to separate all the cells into single cells.

NOTE: If the number of cells in the preparation is low, increase the centrifuge speed up to 2,000–3,000 $\times g$ to spin down the cells. Moreover, using 0.5 mL centrifuge tubes facilitates better visualization of the cell pellet at the bottom of the tube.

4.6. Block the enzymatic reaction by adding 0.15 mL of FBS into the 0.5 mL tube.

4.7. Centrifuge the single-cell suspension at $500 \times g$ for 5 min at 4 °C using a centrifuge equipped with a fixed-angle rotor, as in step 4.4.

4.8. Discard the supernatant and resuspend the cells in 100 µL of ice-cold 1% bovine serum albumin (BSA) solution in PBS in a 0.2 mL microcentrifuge tube.

NOTE: Using 0.2 mL centrifuge tubes enhances the visualization of the single-cell-pellet at the bottom of the tube.

5. Single-cell and single-nucleus analyses

5.1. Resuspend and submit the single-cell preparation for scRNAseq.

5.1.1. Resuspend the single-cell pellet with 100 μ L of ice-cold 1% BSA in PBS in a 0.2 mL tube.

5.1.2. After resuspending the cells for single-cell encapsulation, immediately proceed for single-cell encapsulation and barcoding using a microfluidics-based single-cell partitioning and barcoding system (see the **Table of Materials**).

5.1.3. Before submitting the samples to the Genomics Core, count and inspect the single-cell preparations; ensure the absence of cell aggregates.

NOTE: The aggregation of single cells can be further minimized by increasing the BSA amount up to 2%.

5.2. Resuspend and submit the single-cell preparation for scRNAseq.

5.2.1. Resuspend the cell pellet in 100 μ L of 0.04% BSA in ice-cold 1x PBS and centrifuge the single-cell suspension at 500 $\times g$ at 4 $^{\circ}$ C.

5.2.2. Lyse the single-cell suspension with ice-cold 0.1x lysis buffer (**Table 1**) and incubate for 5 min on ice.

5.2.3. Mix the lysate 10 times with a P-20 pipette and incubate for an additional 10 min.

5.2.4. Add 500 μ L of chilled wash buffer (**Table 1**) to the lysed cells and mix 5 times using a pipette.

NOTE: Use a 70 μ m cell strainer to filter any debris from the cell suspension and transfer them into a 2 mL tube.

5.2.5. Centrifuge the lysate at 500 $\times g$ for 5 min at 4 $^{\circ}$ C. Discard the supernatant and resuspend the nuclei-pellet in the diluted nuclei buffer (150 μ L) (see the **Table of Materials** and **Table 1**). Count and inspect the single-nuclei preparations using a hemocytometer¹¹.

5.2.6. Submit the single-nuclei sample to the Genomics Core for single-nuclei transposition, nuclei partitioning, library preparation, and sequencing.

NOTE: If the initial cell number is low, it is common to observe debris along the nuclei. Therefore, it is recommended to start with a high cell number.

REPRESENTATIVE RESULTS:

Partial carotid ligation surgeries were performed on 44 mice, and the onset of *d-flow* in the LCA

was validated by performing ultrasonography one day post partial ligation surgery. Successful partial ligation surgery causes reduced blood flow velocity and reverses blood flow (disturbed flow) in the LCA³. The carotid arteries were dissected out either at two days or at two weeks post ligation. The lumen of each carotid was subjected to collagenase digestion, and endothelial-enriched single-cells or single-nuclei suspensions were prepared. Single-cell suspensions were pooled from 10 RCAs and LCAs to increase the cell yield. The cells/nuclei prepared were subsequently barcoded and sequenced. For the sc-RNAseq study, the number of single cells obtained was ~9,700. The distribution of cells from 4 samples is shown in **Table 2**.

Likewise, for the single-nuclei ATAC sequencing study, single cells were isolated from 12 RCAs and LCAs that were prepared, subjected to transposase treatment, barcoded, and sequenced. Sequencing was performed for 18,324 single nuclei, which were pooled from 1,291 (2-day RCA [2D-R]), 5,351 (2-day LCA [2D-L]), 5,826 (2-week RCA [2W-R]), and 5,856 (2-week LCA [2W-L]) (**Table 2**). Representative single-cell and single-nuclei preparations as visualized by brightfield microscopy and phase-contrast microscopy are shown in **Figure 2A,B**. The efficiency of single-nuclei preparation from single-cell suspension is shown in **Figure 2C**.

The nuclei (~7,000 each) from 2D (RCAs and LCAs) and 2W (RCAs and LCAs) samples were incubated with a Transposition Mix (Tn5 transposase enzyme and buffer) see the **Table of Materials**) for 60 min at 37 °C following the manufacturer's protocol. Based on the manufacturer's recommendation, a mild detergent condition helped keep the nuclei intact during tagmentation. A master mix, consisting of a Barcoding Reagent, Reducing Agent B, and Barcoding Enzyme, was then loaded onto a microfluidic cell/nuclei encapsulation platform to prepare single-nuclei gel emulsions with barcoding according to the manufacturer's instructions.

Post sequencing, the Cell Ranger Single-Cell Software suite was used for demultiplexing, barcode processing, alignment, and initial clustering of the raw scATACseq and scRNAseq profiles. For the scRNAseq study, the distribution of genes per cell, unique molecular identifier (UMI) per cell, mitochondrial reads per cell, and sequencing saturation information are shown in **Figure 3-C**. Likewise, for the scATACseq study, quality control metrics showing the insert size distribution (nucleosome banding pattern) and normalized TSS enrichment score are shown in **Figure 3D-F**. Additionally, the percent fragment reads in the peaks, peak region fragments, TSS enrichment score, ratio of reads in blacklist genomic sites, and nucleosome signal ratio are shown in **Figure 3G-K**.

Endothelial enrichment was quantitated by comparing this method to that of enzymatic digestion of the whole carotid artery¹². The endothelial cell count from the complete carotid artery digestion was 3–5% of the total cells obtained, whereas this method allowed enrichment of endothelial cells to >50%⁸. Similarly, another single-cell study that used the whole mouse aorta showed that endothelial fraction was <7% of the total cell count. For an in-depth single-cell RNAseq and single-cell ATACseq analysis, readers are requested to refer to⁸.

FIGURE AND TABLE LEGENDS:

Figure 1: Isolation of carotid arteries for single-cell preparation. (A) Anatomical view of the carotid arteries in mice. Red arrows and inset show the isolated left carotid artery after clean up of periadventitial fat. (B) Image shows the location of micro-clips after filling the carotid artery with the digestion buffer. (C) Explanted carotid artery containing digestion buffer. Scale: distance between black lines = 1 mm. (D) A 29 G needle in the lumen of the mouse carotid artery. This step helps replenish the carotid artery with digestion buffer if needed.

Figure 2: Single-cell and single-nuclei preparation from luminal enzymatic digestion of mouse carotid artery. (A) Representative single-cell and single-nuclei preparations. Scale bars = 0.25 mm (B) Representative phase-contrast and Gel-Red images of single-nuclei preps. Scale bars = 0.25 mm. (C) Efficiency of single-nuclei preparation in the left column shows the number of single cells at the start while the right column shows the number of single nuclei after processing with nuclei isolation buffer in different steps.

Figure 3: Standard QC metrics for the scRNAseq and scATACseq study. Violin plots show (A) the distribution of genes per cell (nFeature_RNA), (B) UMI per cell (nCount_RNA), (C) mitochondrial reads per cell (percent mt) for the scRNAseq data. (D and E) show the nucleosome banding pattern for the scATACseq study. The histogram of DNA fragment sizes exhibits a strong nucleosome banding pattern corresponding to the length of DNA wrapped around a single nucleosome. (F) Normalized TSS enrichment score at each position relative to the TSS. The scatter/violin plots show (G) percent fragment reads in the peaks, a measure of sequencing depth, (H) peak region fragments showing the number of fragments overlapping peaks, (I) TSS enrichment score, a ratio between the aggregate distribution of reads centered on TSSs and that flanking the corresponding TSS, (J) blacklist ratio, a ratio of reads in blacklist genomic sites, and (K) nucleosome signal, a ratio of mononucleosomal to nucleosome-free fragments. Abbreviations: scRNAseq = single-cell RNA sequencing; scATACseq = single-cell Assay for Transposase Accessible Chromatin sequencing; QC = quality control; UMI = unique molecular identifier; TSS = transcription start site.

Table 1: Composition of single-nuclei lysis and wash buffers.

Table 2: Single-cell and single-nuclei count from mouse carotid artery luminal digestion. The table also shows means reads/cell and number of genes/cell for scRNAseq data. For the scATACseq data, mean fragments/cell and total reads obtained per sample are shown⁸. Abbreviations: sc-RNAseq = single-cell RNA sequencing; scATA seq = single-cell Assay for Transposase Accessible Chromatin sequencing; 2D = 2-day; 2W = 2-week; R/RCA = right carotid artery; L/LCA = left carotid artery.

DISCUSSION:

This paper provides a detailed protocol to isolate single-cell preparations from the mouse carotid arteries. The influence of *d-flow* on the endothelial cells can be accurately studied if the PCL surgery is performed correctly. It is crucial to correctly identify the branches of the common carotid, such as the external carotid, internal carotid, occipital artery, and superior thyroid artery. Validation of flow patterns by ultrasonography further validates the successful onset of *d-flow*

conditions. Although PCL surgery can be performed on mice irrespective of their age, the preferred age is 10 ± 2 weeks. Older mice and mice with hypercholesterolemic backgrounds generally tend to have more periadventitial fat and stiffer skin.

It is essential to carefully dissect the carotid artery endothelial-enriched single-cell preparations free of the surrounding tissue and periadventitial fat. The lumen of the carotids must be perfused thoroughly to avoid contaminating blood cells in the single-cell preparations. Improper tissue identification and labeling can result in high standard deviation. Careful planning and time management are required for this protocol. A skilled surgeon and operator can take 15–20 min to perform one PCL surgery. Sacrificing, carotid isolation, and luminal enzymatic digestion from each mouse would take an additional 35–40 min. The hands-on processing time from endothelial cell flushing to single-cell/single-nuclei prep is an additional 2 h. Meticulous planning and teamwork are highly recommended.

As with any experimental protocol, some disadvantages and limitations should be considered. The current protocol does not incorporate steps to avoid artifactual activation of immediate early response during the luminal tissue dissociation. It has been reported in the literature that enzymatic digestion can lead to stress signaling events, such as inflammation and apoptosis. This can be addressed by incorporating appropriate control groups in the experimental design. In addition, wet laboratory methods that can minimize the artifactual activation of immediate response during enzymatic digestion, such as cold-active proteases, should be considered^{13,14}.

This protocol can be used for any mouse strain irrespective of its genetic background. However, the endothelial-enriched preparations can best answer research questions pertaining to the changes in endothelium and are therefore well suited for EC-specific knockouts and EC-specific transgenic mice. This single-cell isolation method can be adapted to perform single-cell multi-omics studies and other flow cytometry-based assays such as Imaging Flow Cytometry. The luminal digestion approach could be used for freshly obtained mouse aortas, arteries from large animals (rabbits and pigs), as well as for freshly obtained human vascular explants. Collectively, this method would allow us to fully understand the precise role of blood flow on endothelial function and reprogramming at a single-cell resolution.

ACKNOWLEDGMENTS:



This work was supported by funding from National Institutes of Health grants HL119798, HL095070, and HL139757 to HJ. HJ is also supported by the Wallace H. Coulter Distinguished Faculty Chair Professorship. The services provided by the Emory Integrated Genomics Core (EIGC) were subsidized by the Emory University School of Medicine and were also partly supported by the Georgia Clinical and Translational Science Alliance of the National Institutes of Health under award no. UL1TR002378. The content provided above is solely the authors' responsibility and does not reflect the official views of the National Institutes of Health.

DISCLOSURES:


HJ is the founder of FloKines Pharma. Other authors have no conflicts of interest to declare.

REFERENCES:


- 1 Kumar, S., Kang, D. W., Rezvan, A., Jo, H. Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation. *Laboratory Investigation*. **97** (8), 935–945 (2017).
- 2 Nam, D. et al. Partial carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial dysfunction and atherosclerosis. *American Journal of Physiology Heart and Circulation Physiology*. **297** (4), H1535–1543 (2009).
- 3 Nam, D. et al. A model of disturbed flow-induced atherosclerosis in mouse carotid artery by partial ligation and a simple method of RNA isolation from carotid endothelium. *Journal of Visualized Experiments: JoVE*. (40), e1861 (2010).
- 4 Dunn, J. et al. Flow-dependent epigenetic DNA methylation regulates endothelial gene expression and atherosclerosis. *Journal of Clinical Investigation*. **124** (7), 3187–3199 (2014).
- 5 Kumar, S., Kim, C. W., Son, D. J., Ni, C. W., Jo, H. Flow-dependent regulation of genome-wide mRNA and microRNA expression in endothelial cells in vivo. *Scientific Data*. **1** (1), 140039 (2014).
- 6 Ni, C. W. et al. Discovery of novel mechanosensitive genes in vivo using mouse carotid artery endothelium exposed to disturbed flow. *Blood*. **116** (15), e66–73 (2010).
- 7 Son, D. J. et al. The atypical mechanosensitive microRNA-712 derived from pre-ribosomal RNA induces endothelial inflammation and atherosclerosis. *Nature Communications*. **4**, 3000 (2013).
- 8 Andueza, A. et al. Endothelial reprogramming by disturbed flow revealed by single-cell RNA and chromatin accessibility study. *Cell Reports*. **33** (11), 108491 (2020).
- 9 Stuart, T., Srivastava, A., Lareau, C., Satija, R. Multimodal single-cell chromatin analysis with Signac. *bioRxiv*. doi: 10.1101/2020.11.09.373613 2020.2011.2009.373613 (2020).
- 10 Stuart, T. et al. Comprehensive integration of single-cell data. *Cell*. **177** (7), 1888–1902.e1821 (2019).
- 11 Crowley, L. C., Marfell, B. J., Christensen, M. E., Waterhouse, N. J. Measuring cell death by trypan blue uptake and light microscopy. *Cold Spring Harbor Protocols*. **2016** (7), doi: 10.1101/pdb.prot087155 (2016).
- 12 Li, F. et al. Single-cell RNA-seq reveals cellular heterogeneity of mouse carotid artery under disturbed flow. *Cell Death and Discovery*. **7** (1), 180 (2021).
- 13 Wu, Y. E., Pan, L., Zuo, Y., Li, X., Hong, W. Detecting activated cell populations using single-cell RNA-seq. *Neuron*. **96** (2), 313–329.e316 (2017).
- 14 O'Flanagan, C. H. et al. Dissociation of solid tumor tissues with cold active protease for single-cell RNA-seq minimizes conserved collagenase-associated stress responses. *Genome Biology*. **20** (1), 210 (2019).

A.**B.****C.****D.**

A




B




C

Efficiency	
Single cells	Single Nuclei
10,000	4,800
50,000	28,000
100,000	43,000
200,000	102,000


scRNAseq



scATACseq



pct_reads_in_peaks **peak_region_fragments** **TSS.enrichment** **blacklist_ratio** **nucleosome_signal**



1x single-nuclei lysis buffer

1x Lysis buffer	Stock	Final	2 mL
Tris-HCl (pH 7.4)	1 M	10 mM	20 µL
NaCl	5 M	10 mM	4 µL
MgCl ₂	1 M	3 mM	6 µL
Tween-20	10%	0.10%	20 µL
Nonidet P40	10%	0.10%	20 µL
Digitonin	5%	0.01%	4 µL
BSA	10%	1%	200 µL
Nuclease-free water	-	-	1.732 mL

0.1x single-nuclei lysis buffer

0.1x Lysis buffer	Stock	Final	2 mL
Tris-HCl (pH 7.4)	1x	0.1x	200 µL
Nuclease-free water	-	-	1.8 mL

Single-nuclei wash buffer

Wash Buffer	Stock	Final	2 mL
Tris-HCl (pH 7.4)	1 M	10 mM	20 µL
NaCl	5 M	10 mM	4 µL
MgCl ₂	1 M	3 mM	6 µL
BSA	10%	1%	200 µL
Tween-20	10%	0.10%	20 µL
Nuclease-free water	-	-	1.75 mL


Single-nuclei Nuclei Buffer

Diluted Nuclei Buffer	Stock	Final	1 mL
Nuclei Buffer (20x)	20x	1x	50 µL
see the Table of Materials			
NaCl	5 M	10 mM	4 µL

Table 5.

	Sample	Mice (n)	Study	Single cells	Mean reads/ cell
scRNAseq	2D-R	10	2 day, RCA	1,867	55,593
	2D-L		2 day, LCA	2,119	76,050
	2W-R		2 wk, RCA	1,263	88,631
	2W-L		2 wk, LCA	4,460	34,142
	Sample	Mice (n)	Study	Single cells	Mean fragments/ cell
scATACseq	2D-R	12	2 day, RCA	1,291	24,459
	2D-L		2 day, LCA	5,351	22,201
	2W-R		2 wk, RCA	5,826	19,690
	2W-L		2 wk, LCA	5,856	22,398


Genes/ cell
3,376
3,284
3,537
2,770
Total reads
304,487,130
372,162,757
336,611,489
370,557,062



[Click here to access/download](#)

Table of Materials

Table of Materials updated.xlsx



September 14, 2021

Kind Attention:

Vidhya Iyer, Ph.D.

Review Editor

[JoVE](#)

vidhya.iyer@jove.com

Re: JoVE63128R1 "Endothelial-enriched Single-cell Preparation from Mouse Carotid Artery Lumen for Single-Cell Multi-omics Studies"

Dear Dr. Iyer,

Thank you for reviewing and editing our manuscript and providing our valuable feedback.

Based on your comments and suggestions, we have updated the manuscript.

Our edits are made as a track-changed version while retaining your edits and comments for future reference.

We agree with consolidating Table 1-4. The Table numbers for the rest of the tables have been updated accordingly. The commercial names for equipment/reagents have been moved to the updated Table of Materials.

We have updated the Figure #3 to include links to images with appropriate labels. The Representative Results section and the figure legend for Figure #3 has been updated accordingly.

We also paraphrased the text in the Title, Abstract, Introduction, Discussion and Acknowledgement section to further reduce the overlap.

We have also highlighted the specific text in the Protocol that identifies essential steps for the video.

Thanks and regards,

Hanjoong Jo, Ph.D.

Wallace H. Coulter Distinguished Faculty Chair Professor

Associate Chair for Emory BME

Wallace H. Coulter Department of Biomedical Engineering

Emory University and Georgia Tech

1760 Haygood Drive

Health Sciences Research Bldg E170

Atlanta, GA 30322

You are being carbon copied ("cc:'d") on an e-mail "To" "Hanjoong Jo" hjo@emory.edu
CC: "Sandeep Kumar" sandeepkumar@emory.edu, "Aitor Andueza" aanduez@emory.edu,
"Juyoung Kim" juyoungkim@gmail.com, "Dong Kang" dkang9@emory.edu

Dear Dr. Jo,

Your manuscript JoVE63128R1 "Endothelial-enriched Single-cell Preparation from Mouse Carotid Artery Lumen for Single-Cell Multi-omics Studies" has been editorially reviewed and formatted to meet JoVE's requirements (see **63128_R1_edit** uploaded in this submission). Please go through the comments inserted in **63128_R1_edit** and address them, tracking your changes and retaining mine. Some commercial names had to be removed from the text; please add these to the Table of Materials. Also, please check if changes made (such as consolidation of tables 1 to 4) are OK, and renumber the referenced tables if you're OK with these changes. Please refer to the attached iThenticate report to see if you can paraphrase a few sentences and reduce overlap.

Your revision is due by **Sep 15, 2021**.

To submit a revision, go to the [JoVE submission site](#) and log in as an author. You will find your submission under the heading **Submission Needing Revision**.

Best,

Vidhya Iyer, Ph.D.

Review Editor

[JoVE](#)

vidhya.iyer@jove.com

617.674.1888

Follow us: [Facebook](#) | [Twitter](#) | [LinkedIn](#)

[About JoVE](#)

ELSEVIER LICENSE TERMS AND CONDITIONS

Sep 02, 2021

This Agreement between Dr. Sandeep Kumar ("You") and Elsevier ("Elsevier") consists of your license details and the terms and conditions provided by Elsevier and Copyright Clearance Center.

License Number	5140020514940
License date	Sep 01, 2021
Licensed Content Publisher	Elsevier
Licensed Content Publication	CELL REPORTS
Licensed Content Title	Endothelial Reprogramming by Disturbed Flow Revealed by Single-Cell RNA and Chromatin Accessibility Study
Licensed Content Author	Aitor Andueza,Sandeep Kumar,Juyoung Kim,Dong-Won Kang,Hope L. Mumme,Julian I. Perez,Nicolas Villa-Roel,Hanjoong Jo
Licensed Content Date	Dec 15, 2020
Licensed Content Volume	33
Licensed Content Issue	11
Licensed Content Pages	1
Start Page	108491

End Page 0

Type of Use reuse in a journal/magazine

Requestor type academic/educational institute

Portion figures/tables/illustrations

Number of
figures/tables/illustrations 1

Format both print and electronic

Are you the author of this
Elsevier article? Yes

Will you be translating? No

Title of new article Endothelial-enriched Single Cells Preparation From the lumen of
Mouse Carotid Arteries For Single-Cell multi-omics studies

Lead author Sandeep Kumar, Aitor Andueza, Juyoung Kim, Dong Won Kang,
Hanjoong Jo

Title of targeted journal Journal of Visual Experiment

Publisher JoVE

Expected publication date Dec 2021

Order reference number Jo lab Permission Cell Report 1

Portions Supplementary Table.

Requestor Location Dr. Sandeep Kumar
1760 Haygood Dr NE
E-172

ATLANTA, GA 30322

United States
Attn: Dr. Sandeep Kumar

Publisher Tax ID 98-0397604

Total 0.00 USD

Terms and Conditions

INTRODUCTION

1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at <http://myaccount.copyright.com>).

GENERAL TERMS

2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated.

3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows:

"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier."

4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given.

5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please contact Elsevier's permissions helpdesk [here](#)). No modifications can be made to any Lancet figures/tables and they must be reproduced in full.

6. If the permission fee for the requested use of our material is waived in this instance, please be advised that your future requests for Elsevier materials may attract a fee.

7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.

8. **License Contingent Upon Payment:** While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing process for the transaction, provided that you have disclosed complete and accurate details of your proposed use, no license is finally effective unless and until full payment is received from you (either by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms and conditions or any of CCC's Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may constitute copyright infringement and publisher reserves the right to take any and all action to protect its copyright in the materials.

9. **Warranties:** Publisher makes no representations or warranties with respect to the licensed material.

10. **Indemnity:** You hereby indemnify and agree to hold harmless publisher and CCC, and their respective officers, directors, employees and agents, from and against any and all claims arising out of your use of the licensed material other than as specifically authorized pursuant to this license.

11. **No Transfer of License:** This license is personal to you and may not be sublicensed, assigned, or transferred by you to any other person without publisher's written permission.

12. **No Amendment Except in Writing:** This license may not be amended except in a writing signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).

13. **Objection to Contrary Terms:** Publisher hereby objects to any terms contained in any purchase order, acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC's Billing and Payment terms and conditions. These terms and conditions, together with CCC's Billing and Payment terms and conditions (which are incorporated herein), comprise the entire agreement between you and publisher (and CCC) concerning this licensing transaction. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC's Billing and Payment terms and conditions, these terms and conditions shall control.

14. **Revocation:** Elsevier or Copyright Clearance Center may deny the permissions described in this License at their sole discretion, for any reason or no reason, with a full refund payable to you. Notice of such denial will be made using the contact information provided by you. Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied permissions.

LIMITED LICENSE

The following terms and conditions apply only to specific license types:

15. **Translation:** This permission is granted for non-exclusive world **English** rights only unless your license was granted for translation rights. If you licensed translation rights you may only translate this content into the languages you requested. A professional translator

must perform all translations and reproduce the content word for word preserving the integrity of the article.

16. Posting licensed content on any Website: The following terms and conditions apply as follows: Licensing material from an Elsevier journal: All content posted to the web site must maintain the copyright information line on the bottom of each image; A hyper-text must be included to the Homepage of the journal from which you are licensing at <http://www.sciencedirect.com/science/journal/xxxxx> or the Elsevier homepage for books at <http://www.elsevier.com>; Central Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu.

Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier homepage at <http://www.elsevier.com>. All content posted to the web site must maintain the copyright information line on the bottom of each image.

Posting licensed content on Electronic reserve: In addition to the above the following clauses are applicable: The web site must be password-protected and made available only to bona fide students registered on a relevant course. This permission is granted for 1 year only. You may obtain a new license for future website posting.

17. For journal authors: the following clauses are applicable in addition to the above:

Preprints:

A preprint is an author's own write-up of research results and analysis, it has not been peer-reviewed, nor has it had any other value added to it by a publisher (such as formatting, copyright, technical enhancement etc.).

Authors can share their preprints anywhere at any time. Preprints should not be added to or enhanced in any way in order to appear more like, or to substitute for, the final versions of articles however authors can update their preprints on arXiv or RePEc with their Accepted Author Manuscript (see below).

If accepted for publication, we encourage authors to link from the preprint to their formal publication via its DOI. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help users to find, access, cite and use the best available version. Please note that Cell Press, The Lancet and some society-owned have different preprint policies. Information on these policies is available on the journal homepage.

Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an article that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and editor-author communications.

Authors can share their accepted author manuscript:

- immediately
 - via their non-commercial person homepage or blog
 - by updating a preprint in arXiv or RePEc with the accepted manuscript
 - via their research institute or institutional repository for internal institutional uses or as part of an invitation-only research collaboration work-group
 - directly by providing copies to their students or to research collaborators for their personal use

- for private scholarly sharing as part of an invitation-only work group on commercial sites with which Elsevier has an agreement
- After the embargo period
 - via non-commercial hosting platforms such as their institutional repository
 - via commercial sites with which Elsevier has an agreement

In all cases accepted manuscripts should:

- link to the formal publication via its DOI
- bear a CC-BY-NC-ND license - this is easy to do
- if aggregated with other manuscripts, for example in a repository or other site, be shared in alignment with our hosting policy not be added to or enhanced in any way to appear more like, or to substitute for, the published journal article.

Published journal article (JPA): A published journal article (PJA) is the definitive final record of published research that appears or will appear in the journal and embodies all value-adding publishing activities including peer review co-ordination, copy-editing, formatting, (if relevant) pagination and online enrichment.

Policies for sharing publishing journal articles differ for subscription and gold open access articles:

Subscription Articles: If you are an author, please share a link to your article rather than the full-text. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help your users to find, access, cite, and use the best available version.

Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

If you are affiliated with a library that subscribes to ScienceDirect you have additional private sharing rights for others' research accessed under that agreement. This includes use for classroom teaching and internal training at the institution (including use in course packs and courseware programs), and inclusion of the article for grant funding purposes.

Gold Open Access Articles: May be shared according to the author-selected end-user license and should contain a [CrossMark logo](#), the end user license, and a DOI link to the formal publication on ScienceDirect.

Please refer to Elsevier's [posting policy](#) for further information.

18. For book authors the following clauses are applicable in addition to the above: Authors are permitted to place a brief summary of their work online only. You are not allowed to download and post the published electronic version of your chapter, nor may you scan the printed edition to create an electronic version. **Posting to a repository:** Authors are permitted to post a summary of their chapter only in their institution's repository.

19. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be submitted to your institution in either print or electronic form. Should your thesis be published commercially, please reapply for permission. These requirements include permission for the Library and Archives of Canada to supply single copies, on demand, of the complete thesis and include permission for Proquest/UMI to supply single copies, on demand, of the complete thesis. Should your thesis be published commercially, please reapply for permission. Theses and dissertations which contain embedded PJAs as part of

the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

Elsevier Open Access Terms and Conditions

You can publish open access with Elsevier in hundreds of open access journals or in nearly 2000 established subscription journals that support open access publishing. Permitted third party re-use of these open access articles is defined by the author's choice of Creative Commons user license. See our [open access license policy](#) for more information.

Terms & Conditions applicable to all Open Access articles published with Elsevier:

Any reuse of the article must not represent the author as endorsing the adaptation of the article nor should the article be modified in such a way as to damage the author's honour or reputation. If any changes have been made, such changes must be clearly indicated.

The author(s) must be appropriately credited and we ask that you include the end user license and a DOI link to the formal publication on ScienceDirect.

If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source it is the responsibility of the user to ensure their reuse complies with the terms and conditions determined by the rights holder.

Additional Terms & Conditions applicable to each Creative Commons user license:

CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article and to make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by/4.0>.

CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article, provided this is not done for commercial purposes, and that the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. Further, any new works must be made available on the same conditions. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-sa/4.0>.

CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article, provided this is not done for commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way, and provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, and that the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-nd/4.0>. Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY NC ND license requires permission from Elsevier and will be subject to a fee.

Commercial reuse includes:

- Associating advertising with the full text of the Article

- Charging fees for document delivery or access
- Article aggregation
- Systematic distribution via e-mail lists or share buttons

Posting or linking by commercial companies for use by customers of those companies.

20. Other Conditions:

v1.10

Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.
